Initiate the pivotal Phase 3 trial of AVB-500 in platinum-resistant ovarian cancer
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 2 Mar 2021
- Due
- 31 Mar 2021
- Delivered
- April 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Aravive's ability to initiate a pivotal trial during first quarter 2021, the trial supporting the submission of a biologics license application to the FDA”
What we found
Evidence strength A What the grades mean
The company dosed the first patient in the Phase 3 trial in April 2021, after the first-quarter 2021 deadline for initiating the trial.
-
A Aravive, Inc. 8-K filed 2021-04-27
“We are pleased to announce the first patient dosing of AVB-500, and we are excited about the meaningful difference AVB-500 may provide” ✓ confirmed on the page
-
A Aravive, Inc. 10-Q filed 2021-05-06
“In April 2021, the Company dosed the first patient in our Phase 3 trial of AVB-500 in platinum resistant ovarian cancer.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 3 pivotal trial of AVB-500 in platinum-resistant ovarian cancer
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Aravive, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C513818-025030 · Corrections policy